S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
Log in
NASDAQ:ZEAL

ZEALAND PHARMA/S Stock Forecast, Price & News

$35.64
-0.39 (-1.08 %)
(As of 09/23/2020 11:26 AM ET)
Add
Compare
Today's Range
$35.61
Now: $35.64
$35.64
50-Day Range
$31.62
MA: $36.44
$38.72
52-Week Range
$22.00
Now: $35.64
$44.60
Volume200 shs
Average Volume7,352 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Read More
ZEALAND PHARMA/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$5.85 per share

Profitability

Net Income$-85,670,000.00
Net Margins-214.31%

Miscellaneous

Employees149
Market Cap$1.42 billion
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$35.64
-0.39 (-1.08 %)
(As of 09/23/2020 11:26 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

How has ZEALAND PHARMA/S's stock price been impacted by Coronavirus?

ZEALAND PHARMA/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 26.8% and is now trading at $35.64.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ZEALAND PHARMA/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ZEALAND PHARMA/S
.

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for ZEALAND PHARMA/S
.

How were ZEALAND PHARMA/S's earnings last quarter?

ZEALAND PHARMA/S (NASDAQ:ZEAL) announced its earnings results on Thursday, August, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.27. The business earned $32.62 million during the quarter, compared to analyst estimates of $32.46 million. ZEALAND PHARMA/S had a negative net margin of 214.31% and a negative return on equity of 38.34%.
View ZEALAND PHARMA/S's earnings history
.

What price target have analysts set for ZEAL?

4 brokerages have issued 1-year price objectives for ZEALAND PHARMA/S's shares. Their forecasts range from $41.00 to $43.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts' price targets for ZEALAND PHARMA/S
.

Who are some of ZEALAND PHARMA/S's key competitors?

What other stocks do shareholders of ZEALAND PHARMA/S own?

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the following people:
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
  • Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)
  • Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)
  • Lani Pollworth Morvan, Investor Relations & Communications Officer

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are ZEALAND PHARMA/S's major shareholders?

ZEALAND PHARMA/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.09%), AWM Investment Company Inc. (0.05%) and Rockefeller Capital Management L.P. (0.01%).

Which major investors are selling ZEALAND PHARMA/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., and Rockefeller Capital Management L.P..

Which major investors are buying ZEALAND PHARMA/S stock?

ZEAL stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $35.64.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $1.42 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.

What is ZEALAND PHARMA/S's official website?

The official website for ZEALAND PHARMA/S is www.zealandpharma.com.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.